What is the clinical evidence from this study?

Study design: Other. Intervention: Pateamine vs. Control. Primary outcome: Inhibition of cap-dependent translation.

July 19, 2005Proceedings of the National Academy of SciencesOpen Access

Stimulation of mammalian translation initiation factor eIF4A activity by a small molecule inhibitor of eukaryotic translation

View Full Paper

Ask AI

Bookmark

Key result

Pateamine inhibits eukaryotic translation initiation by selectively binding to and stimulating the RNA-dependent ATPase and helicase activities of eIF4A.

Authors

MBMarie-Ève BordeleauInstitute for Research in Immunology and Cancer JMJames MatthewsUniversity of Oxford JWJoanna M. WojnarCardinal Stefan Wyszyński University in Warsaw

Discussion

Member takes

Implication

May guide eIF4A-targeted inhibitor design; leaves open cardiovascular therapeutic translation pending in vivo validation.

PICO

Intervention / Comparator

Pateamine vs Control

Primary Outcome

Inhibition of cap-dependent translation

Cite This Study

Bordeleau et al. (2005) studied this question. Pateamine vs. Control was evaluated on Inhibition of cap-dependent translation. Pateamine inhibits eukaryotic translation initiation by selectively binding to and stimulating the RNA-dependent ATPase and helicase activities of eIF4A.

synapsesocial.com/papers/6a7073efb27f158178275ea7 https://doi.org/10.1073/pnas.0504249102

View Full Paper

Ask AI

Bookmark

Stimulation of mammalian translation initiation factor eIF4A activity by a small molecule inhibitor of eukaryotic translation

Discussion

Member takes

Implication

PICO

Cite This Study

Stimulation of mammalian translation initiation factor eIF4A activity by a small molecule inhibitor of eukaryotic translation

Discussion

Member takes

Implication

PICO

Cite This Study

Also Consider

Also Consider